Skip to main content
 

Preclinical pharmacokinetic of a lead peptide for bronchopulmonary dysplasia prevention

Friday, September 15, 2017 — Poster Session IV

1:00 p.m. – 2:30 p.m.
FAES Terrace
NCATS
PHARM-1

Authors

  • KM Konrath
  • MD Singleton
  • AQ Wang
  • X Xu

Abstract

Bronchopulmonary dysplasia (BPD) is a complication developed by many premature infants facing respiratory failure. The administration of a ventilator and the hypoxic conditions to treat preterm babies is thought to play a role in the development of BPD. The inflammatory response from these conditions results in abnormal vascular and alveolar development which can lead to mortality as well as long-term neurological and respiratory effects. Current treatment for BPD is corticosteroids which has limited success. There is not currently a known preventative treatment for BPD. As such, NCATS is working with Novare on developing a preventative therapeutic peptide that acts to block the inflammatory response implicated in the development of BPD. The purpose of current study is to assess the stability of the lead peptide in mouse and baboon blood and plasma in order to develop the sample collection procedure for pharmacokinetic (PK) and PK/PD studies and to evaluate pharmacokinetic properties of the lead peptide in preclinical studies.

Category: Molecular Pharmacology